Immunoglobulins Global Market Report 2023 – By Product (IGG, IGA, IGM, IGE, IGD), By Mode Of Delivery (Intravenous Mode of Delivery, Subcutaneous Mode of Delivery), By Application (Hypogammaglobulinemia, Chronic Inflammatory demyelinating polyneuropathy (CIDP) Immunodeficiency Disease, Myasthenia Gravis, Idiopathic thrombocytopenic purpura (ITP) Other Applications) – Market Size, Trends, And Global Forecast 2023-2032

Immunity Boosting Food Products Market Definition

The immunity boosting food products market consists of sales of immunity-boosting food and beverages, and food supplements and related services by entities (organizations, sole traders and partnerships) that manufacture/produce immunity-boosting food and beverage products and food supplements used to boost the body’s immune system. Immunity boosting food products, also referred to as immunity boosters, are used to strengthen people’s bodily immune systems. A healthy immune system protects the body by forming a barrier that prevents invaders, or antigens, from entering the body. If one slips through the barrier, the immune system produces white blood cells and other chemicals and proteins that target and destroy these foreign substances. To boost immunity requires the intake or consumption of certain food that provides additional benefits to the body. It is important to take the right kind of foods in the right quantities to boost immunity. Vitamin C is one of the biggest immune system boosters of all. Immunity boosting food products include lemons, oranges, bell peppers, broccoli, almonds, walnuts, and supplements such as Vitamin C, Vitamin D, and Zinc.

Viral vectors refer to a tool made of a viral genome that has been converted into a plasmid-based technology, modified for safety by deleting several necessary genes, and the viral components have been separated. Whereas, Plasmid DNA refers to a tiny, circular DNA molecule that can be found in some bacteria and other tiny organisms. Physically distinct from chromosomal DNA, plasmids multiply on their own. The main types of products in viral vectors & plasmid DNA are plasmid DNA and viral vectors. A plasmid is a single-stranded, circular DNA molecule that is different from the chromosomal DNA of a cell. Plasmids are found organically in bacterial cells as well as in certain eukaryotes. Plasmid genes frequently confer genetic benefits to bacteria, such as antibiotic resistance. The different diseases include infectious diseases, genetic disorders, cancer, and others, and are used in gene and cancer therapies, viral infections, immunotherapy, formulation development, and others. The several sectors include research institutes, biopharmaceutical companies, and pharmaceutical companies. The global viral vectors and plasmid dna market is segmented - 1) By Product: Plasmid DNA, Viral Vectors 2) By Application: Gene And Cancer Therapies, Viral Infections, Immunotherapy, Formulation Development, Other Applications 3) By Disease: Infectious Diseases, Genetic Disorders, Cancer, Other Diseases 4) By End User: Research Institutes, Biopharmaceutical And Pharmaceutical Companies The global viral vectors & plasmid dna market size grew from $0.8 billion in 2022 to $0.91 billion in 2023 at a compound annual growth rate (CAGR) of 14.8%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The market size of the viral vectors & plasmid dna is expected to grow from $1.47 billion in 2027 at a CAGR of 12.6%. The rise in the global incidence of cancer is driving the viral vector and plasmid DNA market. The major causes of most cancers include obesity, smoking, alcohol, and improper eating habits. According to the American cancer society 2020, an estimated 1.8 million new cancer cases diagnosed and 606,520 cancer deaths in the United States.Furthermore, in January 2022, according to the American Cancer Society, there will likely be 1.9 million new cancer diagnoses and 609,360 cancer-related deaths in the US, or roughly 1,670 fatalities every day. The four most common types of cancer worldwide are lung, prostate, bowel, and female breast cancer, accounting for 43 percent of all new cancer cases.The rise in the global incidence of cancer is expected to boost the demand for the viral vectors and plasmid DNA market over the coming years. Major players in the viral vectors & plasmid DNA market are FUJIFILM Diosynth Biotechnologies, FinVector Vision Therapies, Lonza, Cobra Biologics and Pharmaceutical Services, Brammer Bio, ??n?k???r??r?t??n, Cell and Gene Therapy Catapult, VGXI and MassBiologics. The unaffordable cost of gene therapies is a major challenge in the viral vectors and plasmid DNA market. The prices of gene therapies range from $0.2 million to $2.1 million. For instance, Gilead company's Yescarta is a gene therapy that costs around $0.3 million and Bluebird Bio's Letiglobin is another gene therapy costing around $2.1 million. The high price is due to various factors like government regulations, production costs, and so on. Therefore, the unaffordable cost of gene therapies is limiting the viral vector & plasmid DNA market growth. The companies in the viral vectors and plasmid DNA market are focusing on the launch of viral vector assays to boost gene therapy research. Viral vectors are tools commonly used by molecular biologists to deliver genetic material into cells and viral vector assays is an investigative procedure on viral vector. For example, in November 2022, PerkinElmer, an American testing laboratories company, announced the launch of its "ready-to-use" adeno-associated virus vectors (AAV) detection kits to support researchers working on gene therapies for a variety of diseases. The viral assays are designed to help researchers quickly and easily characterize viral vector particles being produced to enable decision-making for safe and efficient gene transfer. In January 2020, Cognate Bioservices Inc., a US-based company skilled in cell and cell-mediated gene therapy products, acquired Cobra Biologics, which specialised in providing manufacturing services for plasmid DNA and viral vectors, for an undisclosed amount. The acquisition is expected to create a platform for the life cycle management of cell and gene therapy products. Cobra biologics is well established in the development and manufacture of a variety of viral vectors and DNA. The combined Cognate and Cobra expertise is expected to push both the businesses to a better position to respond to current and future market demand. North America is the largest region in the viral vectors and plasmid DNA market in 2022. The Middle East is expected to be the fastest growing region in the global viral vectors & plasmid DNA market analysis. The regions covered in the global viral vectors & plasmid DNA market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the viral vectors & plasmid DNA market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA. The viral vectors and plasmid DNA market consists of sales of adeno-associated viral, adenoviral, lentiviral, and retroviral. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The viral vectors & plasmid DNA market research report is one of a series of new reports from The Business Research Company that provides viral vectors & plasmid DNA market statistics, including viral vectors & plasmid DNA industry global market size, regional shares, competitors with a viral vectors & plasmid DNA market share, detailed viral vectors & plasmid DNA market segments, market trends and opportunities, and any further data you may need to thrive in the viral vectors & plasmid DNA industry. This viral vectors & plasmid DNA market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

Lateral Flow Immunoassay (LFIA) based rapid test is a simple technology-based diagnostic device that is used to determine the presence of a target such as pathogens or biomarkers in samples collected from the human body. These samples may include urine, saliva, blood, sweat and other fluids. The main techniques in lateral flow immunoassay-based rapid testing are competitive assay, sandwich assay, and multiplex detection assay. The competitive assay is used to assess the existence of a target, such as pathogens or biomarkers, in the samples. The applications are infectious disease, pregnancy and fertility, toxicology, and others that are used in hospitals and clinics, diagnostic laboratory, home care, and others. The global lateral flow immunoassay (LFIA) based rapid test market is segmented - 1) By Technique: Competitive Assay, Sandwich Assay, Multiplex Detection Assay 2) By End User: Hospital & Clinic, Diagnostic Laboratory, Home Care, Other End Users 3) By Application: Infectious Disease, Pregnancy & Fertility, Toxicology, Other Applications The global lateral flow immunoassay (LFIA) based rapid test market size is declined from $10.14 billion in 2022 to $9.19 billion in 2023 at a compound annual growth rate (CAGR) of -9.4%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The global lateral flow immunoassay (LFIA) based rapid test market size is expected to decline to $7.32 billion in 2027 at a CAGR of -5.5%. The demand for point-of-care testing under home care settings is expected to drive the Lateral Flow Immunoassay (LFIA) Based Rapid Test market. Point-of-care (POCT) testing is essential for rapid on-site diagnosis and treatment. The most important features for current POCT diagnostic systems are a quick analysis time with a test-to-answer format. Lateral flow immunoassays (LFIA) are widely used as POCTs due to their speed and precision, simplicity, and low cost. For instance, the recent outbreak of coronavirus disease (COVID-19) has increased the significance of these devices to rapid screening and surveillance. Acro Biotech COVID-19 Rapid POC CE-IVD is a lateral flow immunoassay that quantifiably assesses the existence of patient-generated IgG and IgM antibodies to SARS-CoV-2, the causative agent of novel coronaviral disease COVID-19. These antibodies may be detected in whole blood, serum, or plasma samples in the test cassette. OZO has developed three different variations of its products using the Latex Enhanced Lateral Flow Immunoassays (LFIAs) method for testing COVID-19. Therefore, the need for point-of-care testing under home care settings is expected to drive the Lateral Flow Immunoassay (LFIA) Based Rapid Test market. Major players in the lateral flow immunoassay (LFIA) based rapid test market are Abbott Laboratories, F. Hoffmann-La Roche, Danaher Corporation, Siemens AG, Becton, Dickinson and Company, bioMérieux, Bio-Rad Laboratories, Thermo Fisher Scientific, QIAGEN NV, and Hologic Inc. Low sensitivity of Lateral Flow Immunoassay (LFIA) Based Rapid Test is expected to limit the market. The sensitivity of the test is mainly the ability of the test to correctly identify those with the disease, which is low for Lateral Flow Immunoassay (LFIA) Based Rapid Test compared to other methods that may, in some cases, require a re-test for confirmation. according to a study conducted by researchers, including those from the Harvard medical school in the USA and also the University of British Columbia, Canada. The medical databases and preprint servers were searched from January 1 to April 30, 2020, for studies measuring the sensitivity and specificity of the COVID-19 antibody test compared to the control test. It had been found that pooled sensitivities were consistently lower for the lateral flow immunoassay (LFIA) test compared to other test methods. The low level of sensitivity is anticipated to restrain the market growth for Lateral Flow Immunoassay (LFIA) based rapid test. Companies are collaborating to launch new products. In May 2020, Lateral Flow Diagnostic Company Mologic Ltd., which has teamed up with Biosure Ltd., the developer of the only CE-approved HIV home testing kit, to develop a COVID-19 antibody self-test. The companies combine Mologic's validated IgG lateral flow test strip with Biosure's test kit. In July 2020, MP Biomedicals Asia-Pacific Pte Ltd collaborated with a Singapore company A*STAR to create the ASSURE® SARS-CoV-2 IgG / IgM rapid antibody test kit to detect IgG and IgM antibodies in a person infected with SARS-CoV-2. The kit delivers precise results in very less time as less as 15 minutes and uses the lateral flow method. In April 2020, True Diagnostics, a leading US-based Point of Care (POC) company, partnered with Veravas and Infectolab Americas to create and distribute a fast, point-of-care immunoassay for SARS-CoV-2, the VeraTest SARS-CoV-2 IgA / IgG Fast Test will be developed to detect immunoglobulin A and immunoglobulin G antibodies to SARS-CoV-2 in the blood within 15 minutes. The test combines True Diagnostics, TrueDx lateral flow immunoassay technology with Veravas, VeraPrep clean, and VeraPrep capture technologies designed to remove cross-reaction antibodies and ensure the detection of only SARS-CoV-2-specific antibodies. Veravas is an emerging US-based diagnostic company. Infectolab Americas is a US-based laboratory specialized in lab testing for tick-borne disease. North America was the largest region in the lateral flow immunoassay (LFIA) based rapid test market in 2022. Asia-Pacific was the second largest region in the global lateral flow immunoassay (LFIA) based rapid test market. The regions covered in the global lateral flow immunoassay (LFIA) based rapid test market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa. The countries covered in the lateral flow immunoassay (LFIA) based rapid test market are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, the UK, and the USA. Lateral Flow Immunoassay (LFIA) based rapid test market consits of sales of conjugarte pads, nitrocellulose membrane and absorbent pad. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The lateral flow immunoassay (LFIA) based rapid test market research report is one of a series of new reports from The Business Research Company that provides lateral flow immunoassay (LFIA) based rapid test market statistics, including lateral flow immunoassay (LFIA) based rapid test industry global market size, regional shares, competitors with a lateral flow immunoassay (LFIA) based rapid test market share, detailed lateral flow immunoassay (LFIA) based rapid test market segments, market trends and opportunities, and any further data you may need to thrive in the lateral flow immunoassay (LFIA) based rapid test industry. This lateral flow immunoassay (LFIA) based rapid test market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Bi-specific MAbs or bispecific monoclonal antibodies refer to antibodies that have two binding sites and are designed to bind to two antigens that are either distinct or have two different epitopes. Monoclonal antibodies (MoAbs) do not have the clinical therapeutic effects of BsAbs, which have a wide range of applications for the treatment of different diseases as well as tumour immunotherapy. The main types of bi-specific are catumaxomab (removal), blinatumomab, duligotumab, and SAR 156597. Catumaxomab is a rat-mouse hybrid monoclonal antibody used to treat malignant ascites, a condition that occurs in people who have metastasizing cancer. The various product types including in vivo, and in vitro are used for the treatment of cancer, autoimmune diseases, inflammatory diseases, infectious diseases, microbial diseases, and others. The bispecific monoclonal antibodies are used by hospitals, research institutes, and others. The global BI-specific MAbS market is segmented - 1)By Type: Catumaxomab (Removab), Blinatumomab, Duligotumab, SAR 156597 2)By Product Type: In Vivo, In Vitro 3)By Indication: Cancer, Autoimmune Diseases, Inflammatory Diseases, Infectious Diseases, Microbial Diseases, Other Indications 4)By End Use: Hospitals, Research Institutes, Other End-Users The global bi-specific mabs market size grew from $5.13 billion in 2022 to $6.72 billion in 2023 at a compound annual growth rate (CAGR) of 31.1%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The market size of the bi-specific mabs is expected to grow from $13.16 billion in 2027 at a CAGR of 18.3%. The increasing prevalence of cancer and other chronic diseases is projected to contribute to the growth of the bispecific monoclonal antibodies market over the forecast period. Bispecific monoclonal antibodies are developed for the treatment of various cancers, infectious diseases, central nervous system disorders, and autoimmune disorders. Bispecific monoclonal antibodies are considered to be more effective than monoclonal antibodies (moAbs) as these target two or more tumor antigens on cells to disrupt cancer progression. For instance, in February 2022, according to the World Health Organization, a Switzerland-based international public health agency of the United Nations, cancer will be the leading cause of deaths across the globe, causing almost 10 million fatalities in 2020, or almost one in every six deaths. Breast, lung, colon, rectum, and prostate cancers are the most prevalent types of cancer. Additionally, in October 2022, according to the Centers for Disease Control and Prevention, chronic diseases will be among the most prevalent diseases, with 6 out of 10 adults suffering from at least one chronic disease in the USA. Therefore, a rising number of chronic diseases, including cancer, is anticipated to propel the demand for bi-specific MAbs to treat these diseases effectively. Major players in the bi-specific MAbs or bispecific monoclonal antibodies market are Johnson & Johnson, Novartis AG, Hoffmann-La Roche Ltd., Novo Nordisk A/S, Bayer AG, Thermo Fisher Scientific, Inc., Bistro-Myers Squibb. Mylan N.V., Daiichi Sankyo Company Ltd. and Abbott. The availability of various alternative treatment methods for cancer is expected to limit the growth of the bispecific monoclonal antibodies market. Alternative cancer treatment therapies and methods used for the treatment of cancer including dietary treatments, acupuncture, homeopathy, and herbal remedies are gaining popularity in recent years attributed to side effects of chemotherapeutic anticancer agents. For instance, Ayurvedic medicine, an ancient Indian system of medicine uses a range of techniques and treatments for cancer. Many of the herbs used in Ayurveda have anti-cancer properties, for example, andrographispaniculata. According to the World Health Organization (WHO), some nations are still responding to plant-based treatment as their main medicine source, and developing nations are using the benefits of natural compounds for therapeutic purposes. Therefore, this affects the biologic sales and hence impacts the bi-specific MAbS market. Also, the global homeopathic product market is projected to reach $18.6 billion by the end of 2027, growing at a CAGR of 14% during the forecast period. The less expensive alternative medicines increase competition for the biologics market, thereby, hindering the growth of the bi-specific MAbs market shortly. Companies in the bi-specific MAbS market are increasingly investing in various strategic initiatives such as collaborations and partnerships to expand the product portfolio and geographical presence of the company. For instance, in June 2020, AbbVie Inc., a US-based biopharmaceutical company entered into a collaboration agreement with Genmab A/S, a Danish biotechnology company, to develop and commercialize antibody therapeutics for cancer treatment. The companies together will work on three early-stage bispecific antibody candidates of Genmab A/S including DuoHexaBody-CD37, epcoritamab, and DuoBody-CD3x5T4 along with discovering new antibody therapeutics. Moreover, in July 2020, Atreca, Inc., a US-based clinical-stage biotechnology company, and Xencor, Inc. entered into a strategic partnership to develop, discover, and commercialize Novel T cell engaging bispecific antibodies as potential therapeutics for oncology treatment. Xencor, Inc. is a US-based biopharmaceutical company developing engineered monoclonal antibodies for cancer and autoimmune disease treatment. In August 2020, AbCellera, a biotechnology firm based in Canada, completed the acquisition of the OrthoMab bispecific platform from Dualogics for an undisclosed amount. The acquisition integrated OrthoMab into AbCellera’s existing technology stack, which provided the industry with a rapid and complete solution for generating tailored, stable, and developable bispecific antibodies Dualogics is a US-based biotechnology company specialized in protein engineering for improving antibody therapeutics. North America was the largest region in the bi-specific MAbS market in 2022. The regions covered in the global bi-specific MAbs or bispecific monoclonal antibodies market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The countries covered in the global bi-specific MAbs or bispecific monoclonal antibodies market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK and USA. The bi-specific MAbs or bispecific monoclonal antibodies market consists of sales of trifunctional antibodies, chemically linked Fabs, and bispecific T cell engagers. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The bi-specific MAbs or bispecific monoclonal antibodies market research report is one of a series of new reports from The Business Research Company that provides bi-specific MAbs or bispecific monoclonal antibodies market statistics, including bi-specific MAbs or bispecific monoclonal antibodies industry global market size, regional shares, competitors with a bi-specific MAbs or bispecific monoclonal antibodies market share, detailed bi-specific MAbs or bispecific monoclonal antibodies market segments, market trends and opportunities, and any further data you may need to thrive in the bi-specific MAbs or bispecific monoclonal antibodies industry. This bi-specific MAbs or bispecific monoclonal antibodies market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

Immunochemistry is the study of the components and functions of the immune system. Immunochemistry diagnostic devices and equipment are designed to diagnose diseases or conditions by studying the functions of the immune system through the analysis of the nature of specific proteins, antigens, antibodies, and their interactions. The main product types are immunochemistry analyzers, immunochemistry stainers, incubators, microscopes, centrifuges, autoclaves, and consumables. Centrifuges are machines that use centrifugal force for separating substances of different densities, removing moisture, or simulating gravitational effects. The immunochemistry analyzers are chemiluminescence immunoassay (CLIA) analyzers, immunofluorescence (IFA) analyzers, enzyme immunoassay (EIA) analyzers, radioimmunoassay (RIA) analyzers, enzyme-linked fluorescent assay (ELFA) systems, and multiplexed assay systems. The immunochemistry stainers are automated and semi-automated. The consumables are antibodies, antigens, enzymes, reagents, stains, buffers, disposables, and others. The various applications are endocrinology, oncology, cardiology, therapeutic drug development and monitoring, infectious disease testing, drug abuse testing, and others. They are used by various end-users, including hospitals and clinics, diagnostic laboratories, research labs, and institutes, biopharmaceutical and biotechnology companies, and others. The global immunochemistry diagnostic devices and equipment market is segmented - 1) By Product Type: Immunochemistry Analyzers, Immunochemistry Stainers, Incubators, Microscopes, Centrifuges, Autoclaves, Consumables 2) By Application: Endocrinology, Oncology, Cardiology, Therapeutic Drug Development & Monitoring, Infectious Disease Testing, Drugs Of Abuse Testing, Other Applications 3) By End Users: Hospitals And Clinics, Diagnostic Laboratories, Research Labs And Institutes, Biopharmaceutical And Biotechnology Companies, Other End Users 4) By Immunochemistry Analyzers: Chemiluminescence Immunoassay (CLIA) Analyzers, Immuno Fluorescence (IFA) Analyzers, Enzyme Immunoassay (EIA) Analyzers, Radioimmunoassay (RIA) Analyzers, Enzyme Linked Fluorescent Assay (ELFA) Systems, Multiplexed Assay Systems 5) By Immunochemistry Stainers: Automated Stainers, Semi-Automated Stainers 6) By Consumables: Antibodies, Antigens, Enzymes, Reagents, Stains, Buffers, Disposables, Other Consumables The global immunochemistry diagnostic devices and equipment market size will grow from $16.22 billion in 2022 to $17.59 billion in 2023 at a compound annual growth rate (CAGR) of 8.5%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The market size of global immunochemistry diagnostic devices and equipment is expected to grow to $21.86 billion in 2027 at a CAGR of 5.6%. An increase in the incidence of target diseases is a major driver for the immunochemistry diagnostic devices and equipment market. The incidence rate of diseases such as viral infections, cardiovascular diseases, cancer, or hormonal disorders is increasing worldwide, mainly due to poor lifestyle choices. For example, according to the American Heart Association, cardiovascular disease is the leading global cause of death, accounting for over 17.6 million deaths per year. This number is expected to grow to over 23.6 million by 2030. Major players in the immunochemistry diagnostic devices and equipment market are Abbott Diagnostics, Roche Diagnostics, Siemens Healthcare Diagnostics, Diamond Diagnostics, Dynex Technologies, Grifols, Hycor Biomedical, Immunodiagnostic Systems, Inova Diagnostics, and LabCorp. Stringent regulatory policies related to the approval of immunoassay instruments and consumables are a major restraint for the immunochemistry diagnostic devices and equipment market. Immunochemistry devices and equipment manufacturers are required to obtain multiple and separate clearances from the Food and Drug Administration (FDA) for launching their products. The entire process of regulatory approval is time-consuming, with a minimum of about 18-30 months required for approval of class III devices and around 6-9 months required for approval of class II devices. Companies in the immunochemistry diagnostic devices and equipment market are increasingly investing in automated immunoassay systems. This is mainly because automation has led to an increase in the capabilities of diagnostic devices in testing higher volumes of patient specimens. In addition, the development of various integrated clinical chemistry systems has immensely improved the efficiency of the analytical phase of clinical chemistry laboratory testing and led to further automation. For example, ichroma-50 is an automatic immunoassay analyzer of Boditech Med Inc. that measures the concentration of the targeted analyte in body fluids such as blood, urine, and other samples in a few minutes, and reduces the labor cost and human error in the process. In the USA, the immunochemistry diagnostic devices and equipment market is regulated by the U.S. Food and Drug Administration (FDA), and all diagnostic laboratory tests are regulated by the clinical laboratory improvement amendments of 1988 (CLIA), which is administered by the Centers for Medicare & Medicaid Services (CMS). A CLIA/FDA compliant laboratory is required to file a PMA/510(k) for market approval of any immunochemistry device. Hence, the regulatory scenario related to immunochemistry diagnostic devices and equipment will keep a check on the companies that manufacture these devices and equipment. North America was the largest region in the global immunochemistry diagnostic devices and equipment market in 2022. Asia-Pacific was the second-largest region in the immunochemistry diagnostic devices and equipment market report. The regions covered in the immunochemistry diagnostic devices and equipment analysis report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The countries covered in the immunochemistry diagnostic devices and equipment market are Brazil, China, France, Germany, India, Indonesia, Japan, South Korea, Russia, the UK, the USA, and Australia. The immunochemistry diagnostic devices and equipment market consists of sales of chemiluminescence immunoassay (CLIA) analyzers, immunofluorescence (IFA) analyzers, enzyme immunoassay (EIA) analyzers, radioimmunoassay (RIA) analyzers, enzyme-linked fluorescent assay (ELFA) systems, and multiplexed assay systems that are used in immunochemistry diagnostics. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The immunochemistry diagnostic devices and equipment market research report is one of a series of new reports from The Business Research Company that provides immunochemistry diagnostic devices and equipment market statistics, including immunochemistry diagnostic devices and equipment industry global market size, regional shares, competitors with a immunochemistry diagnostic devices and equipment market share, detailed immunochemistry diagnostic devices and equipment market segments, market trends and opportunities, and any further data you may need to thrive in the immunochemistry diagnostic devices and equipment industry. This immunochemistry diagnostic devices and equipment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Drug delivery devices are used to deliver specific drugs to a specific part of the body to cure diseases. Drug delivery devices used in various patient care settings, such as hospitals, diagnostic centers, clinics, and home care settings, are included in this market. The main routes of administration of drug delivery devices is oral drug delivery, injectable drug delivery, topical drug delivery, ocular drug delivery, pulmonary drug delivery, nasal drug delivery, transmucosal drug delivery, and implantable drug delivery. Oral drug delivery is a route of drug delivery in which a tablet or capsule is administered into the alimentary canal of a human being. The patient care settings is hospitals, diagnostic centres, ambulatory surgery centres/clinics, home care settings, and others. The various applications involved are cancer, infectious diseases, respiratory diseases, diabetes, cardiovascular diseases, autoimmune diseases, central nervous system disorders, and others. The global drug delivery devices market is segmented - 1) By Route Of Administration: Oral Drug Delivery, Injectable Drug Delivery, Topical Drug Delivery, Ocular Drug Delivery, Pulmonary Drug Delivery, Nasal Drug Delivery, Transmucosal Drug Delivery, Implantable Drug Delivery 2) By Patient Care Setting: Hospitals, Diagnostic Centers, Ambulatory Surgery Centers/Clinics, Home Care Settings, Other Patient Care Settings 3) By Application: Cancer, Infectious Diseases, Respiratory Diseases, Diabetes, Cardiovascular Diseases, Autoimmune Diseases, Central Nervous System Disorders, Other Applications The global drug delivery devices market size will grow from $81.13 billion in 2022 to $87.65 billion in 2023 at a compound annual growth rate (CAGR) of 8.0%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The market size of global drug delivery devices is expected to grow from $115.09 billion in 2027 at a CAGR of 7.0%. The rising prevalence of chronic diseases such as cardiovascular diseases, diabetes, cancer and other diseases is expected to drive the drug delivery devices market. According to the world health organization (WHO), by 2020, chronic diseases will account for almost three-quarters of all deaths worldwide, and 71% of deaths due to ischemic heart disease (IHD), 75% of deaths due to stroke, and 70% of deaths due to diabetes will occur in developing countries. There are various routes of drug administration for medical drugs. The selection of the route depends on three factors - the effect desired; the type of the disease and the type of the product. Currently, the development of new drug delivery systems plays a major role in the pharmaceutical industry. Research and development (R&D) in drug delivery are increasing throughout the world due to the increasing prevalence of these diseases. Most pharmaceutical companies are focusing on multiple drug delivery technologies for creating excellent advantages and better outcomes for their marketed products. Hence, the increasing prevalence of chronic diseases is resulting in increased consumption of therapeutic drugs and therapies, and this factor is expected to act as a driver for the growth of the drug delivery devices market. Major players in the drug delivery devices market are F. Hoffmann-La Roche Ltd., 3M Company, Pfizer Inc., Baxter International, BD, Novartis AG, Gerresheimer AG, Johnson & Johnson Services, Inc., Bayer AG, and GlaxoSmithKline PLC. The regulatory changes related to medical devices is expected to restrain the growth of the drug delivery devices market. The companies operating in the market are required to adapt according to the changes in the regulatory framework, which may limit business at the bottom line. Also, companies will have to bear the heavy cost of adapting to the changing regulatory framework. Also, the sudden changes in the regulatory framework related to medical devices can result in losses, fines, and penalties at a global level. The new MDSAP will come into effect in 2020 and is adopted by regulators in the US, Canada, Japan, Brazil, and Australia. Following the changes, in Canada, all the medical device manufacturers including drug delivery products manufacturers, will have to comply with the requirements of MDSAP and are required to submit the MDSAP reports to the regulatory body in order to obtain or maintain the device licenses, resulting in high costs and time loss. Thus, the growth of the drug delivery devices market is limited by the regulatory changes related to medical devices. The microneedle (MN), is a highly efficient and versatile medical device technology, due to its prominent properties including painless penetration, low cost, excellent therapeutic efficacy, and relative safety. The major players operating in the global microneedle drug delivery system include 3M, Vetter Pharma International GmbH, nano Biosciences LLC., Nano Pass and more. The microneedles are fabricated using biodegradable polymers in which drugs or vaccines are encapsulated in the microneedles. Once, the microneedles dissolve in the skin, the drug gets released. This novel delivery method allows a wider variety of molecules to pass the skin’s barrier, thus allowing the transdermal delivery to be applied to a large range of clinical applications, including diabetes, severe osteoporosis, and influenza vaccination. Companies in the drug delivery devices market are collaborating with other companies within the industry in order to strengthen their product portfolio as well as expand their footprint across different geographies. For example, in October 2022, Nemera, a French pharmaceuticals company, partnered with Zollner Elektronik AG to develop electronic drug delivery systems. Zollner would provide its design, development, and manufacturing capabilities to help Nemera develop electronic drug delivery system. In August 2020, Sulzer, a Swiss-based engineering and manufacturing firm acquired Haselmeier GmbH for $118m. The acquisition of Haselmeier will allow Sulzer to complement its healthcare portfolio, in addition to leveraging its APS expertise in precision injection moulding to expand its presence in the drug delivery devices market. Haselmeier GmbH, a Swiss-German drug delivery device developer and manufacturer. North America was the largest region in the drug delivery devices market in 2022. Asia-Pacific was the second-largest region in the drug delivery devices market report. The regions covered in the drug delivery devices industry report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the drug delivery devices market are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, and USA. The drug delivery devices market consists of sales of instruments such as smart pills, inhalers and nebulizers, drug-eluting stents, safety syringes, and transdermal patches. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The drug delivery devices market research report is one of a series of new reports from The Business Research Company that provides drug delivery devices market statistics, including drug delivery devices industry global market size, regional shares, competitors with a drug delivery devices market share, detailed drug delivery devices market segments, market trends and opportunities, and any further data you may need to thrive in the drug delivery devices industry. This drug delivery devices market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Orphan drugs refer to drugs that are specifically designed to treat an uncommon medical problem. It might be characterised as medicines that address public health needs but are not produced by the pharmaceutical industry due to financial constraints. Since a chemical may be used to treat a common condition but not have been designed for another, more rare indication, the indications of a medicine may likewise be called "orphan." The main types of orphan drugs are biological and non-biological. The various therapy areas include oncology, blood, the central nervous system, endocrine, cardiovascular, respiratory, and immunomodulatory use for the treatment of oncology, hematology, neurology, cardiovascular, and others. Haematology is the study of blood and blood disorders.The drugs are distributed through hospital pharmacies, retail pharmacies, and online sales. The global orphan drugs market is segmented - 1) By Therapy Area: Oncology, Blood, Central Nervous System, Endocrine, Cardiovascular, Respiratory, Immunomodulatory 2) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Online Sales 3) By Drug Type: Biological, Non-Biological 4) By Disease Type: Oncology, Haematology, Neurology, Cardiovascular, Other Disease Types The global orphan drugs market size grew from $154.81 billion in 2022 to $170.77 billion in 2023 at a compound annual growth rate (CAGR) of 10.3%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The market size of orphan drugs is expected to grow from $293.6 billion in 2027 at a CAGR of 14.5%. The rising prevalence of rare diseases is a key factor driving the growth of the orphan drugs market. Any disease that affects a small percentage of the population is rare. Rare disease treatments often require a cold chain, a supply chain regulated by the temperature that is not readily accessible in all countries. Orphan diseases or rare diseases occur rarely among people (i.e. 7 out of 10,000). However, globally, the prevalence of rare diseases is increasing in recent years. For instance, in January 2022, according to an article shared by the American Cancer Society, in USA, There are about 54,000 new instances of oropharyngeal or oral cancer each year. 11,230 people lose their lives to oropharyngeal or oral cancer. The average age of most people diagnosed with these cancers is 63, but they can occur in young people. Just over 20% (1 in 5) of cases occur in patients younger than 55. Thus, the rising prevalence of rare diseases is driving the growth of the orphan drugs market. Major players in the orphan drugs market are Bristol-Myers Squibb Company, Celgene Corporation, F. Hoffmann-La Roche Ltd., Amgen, Biogen, Bayer, Novartis AG, GlaxoSmithKline PLC., Johnson & Johnson, AbbVie Inc., Eli Lilly and Company, Alexion Pharmaceuticals, Shire, Novo Nordisk, AstraZeneca, Eisai, Daiichi Sankyo, Merck, Teva Pharmaceutical Industries, Actelion Pharmaceuticals Ltd., and Aegerion Pharmaceuticals. The lack of supportive government policies hinders the orphan drugs market. Due to the lack of relevant policies for orphan drugs, certain drugs do not receive any special recognition or priority for approval by regulatory authorities. Medgenome Labs Ltd., the global research partner in accelerating insights into complex genetic diseases, pointed out that companies manufacturing orphan drugs frequently drop out in foreign markets due to a lack of government funding. For example, orphan medical products (OMPs) in India, due to a lack of proper regulations and clear guidelines, do not obtain tax cuts or exemptions from customs duties. Therefore, the lack of supportive government policies limits the growth of the orphan drugs market. Approval of biological orphan drugs for multiple indication act as a key trend driving the growth of the orphan drugs market. The biological drugs are used for treating rare diseases such as cancer with fewer side effects that have a high prevalence rate in the developed world. For Instance, to launch the company’s biological orphan drug development program Cardax, Inc. announced that it has been engaged with biological orphan drug expert Frederick D. Sancilio, Ph.D. For the development of commercial products, the companies are focused on obtaining biological orphan drugs to increase their revenue. In October 2020, Retrophin Inc., a US-based biopharmaceutical company, acquired Orphan Technologies for $90 million. This agreement adds OT-58, a brand-new enzyme replacement medication for the treatment of classic homocystinuria that is now in Phase 1/2 research. The acquisition increases the number of possible first-in-class treatments for rare diseases in the pipeline. Orphan Technologies is a Switzerland-based clinical-stage biopharmaceutical company focused on the development of OT-58. North America was the largest region in the global orphan drugs market in 2022. Middle East is expected to be the fastest growing region in the orphan drugs market report during the forecast period. The regions covered in the orphan drugs analysis report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The countries covered in the orphan drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, the UK, and the USA. The orphan drugs market consists of sales of ivacaftor and alglucerase. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organisations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the chain or as part of other products. The orphan drugs market research report is one of a series of new reports from The Business Research Company that provides orphan drugs market statistics, including orphan drugs industry global market size, regional shares, competitors with an orphan drugs market share, detailed orphan drugs market segments, market trends and opportunities, and any further data you may need to thrive in the orphan drugs industry. This orphan drugs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

Autoimmune diseases diagnosis are the diseases in which the production of antibodies takes place in the body which attacks and destroys own healthy cells in the body. These include Crohn's disease, rheumatoid arthritis, Hashimoto’s disease, multiple sclerosis, Grave’s disease, psoriasis, coeliac disease, type 1 diabetes, lupus and inflammatory bowel syndrome, and are diagnosed by immunological tests. The main test types of autoimmune disease diagnosis are routine laboratory tests, autoantibodies tests, immunologic tests, and other tests. Autoantibody tests are used to aid in the diagnosis of autoimmune diseases. The different products include consumables and assay kits, instruments and are used by various sectors such as clinical laboratories, hospitals, and others. The global autoimmune disease diagnosis market is segmented - 1) By Product: Consumables & Assay Kits, Instruments 2) By Test Type: Routine Laboratory Tests, Autoantibodies Tests, Immunologic Tests, Other Tests 3) By End User: Clinical Laboratories, Hospitals, Other End Users The global autoimmune disease diagnosis market size will grow from $5.15 billion in 2022 to $5.56 billion in 2023 at a compound annual growth rate (CAGR) of 7.9%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The market size of global autoimmune disease diagnosis is expected to grow to $7.55 billion in 2027 at a CAGR of 8.0%. A high incidence of autoimmune diseases contributed to the growth of the autoimmune disease diagnosis market. According to the Autoimmune Registry Inc. (ARI) first comprehensive list of Autoimmune Diseases published in 2020, between 15 and 30 million people in the United States suffer from autoimmune disease, making it the nation's largest class of illness, and it primarily affects women aged 20 to 40. Therefore, increasing incidence of autoimmune diseases across the globe is driving the growth of the autoimmune disease diagnosis market. Major players in the autoimmune disease diagnosis market are Thermo Fisher Scientific, Siemens Healthineers, Abbott, Danaher, Bio-Rad Laboratories, Trinity Biotech, HYCOR Biomedical, EUROIMMUN AG, AESKU GROUP GMBH & CO. KG and F. Hoffmann-La Roche Ltd. The high cost of diagnostic tests is a major challenge for the growth of the autoimmune disease diagnosis market. According to a survey by the National Adrenal Diseases Foundation (NADF), the cost for initial diagnosis of Addison’s disease is $1,680 per patient and according to the reports of Vasculitis Foundation of America, vasculitis affects 1 in 20 Americans and the total cost for vasculitis patient per year is $9.7 billion. According to the estimations of The National Institutes of Allergy and Infectious Diseases (NIAID), the annual cost of treating an autoimmune disease in the US is greater than $100 billion and says that annual direct and indirect cost to treat rheumatoid arthritis in the US is $10.9 billion and $8.4 billion respectively. The high cost of diagnosis is increasing the cost burdens on the patients impacting the growth of the autoimmune disease diagnosis market Biosensors and nano biosensors for rapid detection is a novel tool for the detection of antibodies in the autoimmune disease diagnosis market. They are highly preferred because of low cost, high sensitivity, simple to use, multiplexing abilities and rapid diagnosis. Besides measuring the quantity of antibodies in human blood serum with extremely high sensitivity, it also quantifies the activity of antibodies as the assay employs portable optical label-free biosensors based on the spectral correlation interferometry. This point of care technology gives a more integrated, informative, timely and precise diagnosis of autoimmune diseases when compared to the conventional ones. North America was the largest region in the autoimmune disease diagnosis market in 2022. Western Europe was the second largest region in the autoimmune disease diagnosis market share. The regions covered in the global autoimmune disease diagnosis market analysis report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The countries covered in the autoimmune disease diagnosis market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, the UK, and the USA. The autoimmune disease diagnosis market includes revenue earned by diagnostic assay kits, reagents, consumables and instruments used for the diagnosis of autoimmune diseases. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The autoimmune disease diagnosis market research report is one of a series of new reports from The Business Research Company that provides autoimmune disease diagnosis market statistics, including autoimmune disease diagnosis industry global market size, regional shares, competitors with a autoimmune disease diagnosis market share, detailed autoimmune disease diagnosis market segments, market trends and opportunities, and any further data you may need to thrive in the autoimmune disease diagnosis industry. This autoimmune disease diagnosis market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.